Under the deal, Median and the university's Liver Center will jointly conduct a clinical study to validate the vendor's iBiopsy artificial intelligence (AI) technology for characterizing liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) on MRI. Specifically, the retrospective study will include over 300 patients and will quantify iBiopsy's ability to discriminate between early and advanced fibrosis in NASH patients, according to the company.
Dr. Kathryn Fowler of UC San Diego will serve as principal investigator. Initial results from the study are currently expected in the first quarter of 2022, Median said.
Copyright © 2021 AuntMinnie.com